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Previous studies have shown  that immune serums made with mouse lym- 
phoma cells as  antigens can act powerfully  and to some extent specifically 
in ~ivo on the ce]ls of several mouse lymphomas, though none has proved power- 
ful enough to overcome advanced lymphomatosis in susceptible  mice (1). In 
the initial tests of the work now  to be reported,  conjugates were made by 
coupling  diazotized  arsanilic  acid  (4-arsonophenyldiazotate)  with  an  anti- 
Lymphoma 6C3HED-immune rabbit serum,  on the assumption that the at- 
tached arsenic might enhance the effects of the immune globulins on lymphoma 
cells of this type in vivo. In  several experiments,  arsenic-azo-immune  globulin 
preparations indeed acted much more powerfully upon Lymphoma 6C3HED 
cells in  vivo  than did the immune globulins alone,  bringing  about the com- 
plete regression of established  6C3HED lymphomas in susceptible ZBC mice 
without harming the latter perceptibly,  while untreated control animals regu- 
larly died with lymphomatosis. But further experiments  promptly disclosed 
that  arsenic-azo  preparations  made  with  a  variety of other  proteins  (e.g., 
bovine  albumin, horse  or bovine  globulin,  ovalbumin, and casein)  were also 
effective against the proliferating lymphoma cells in vivo---and,  so far as this 
could be judged, fully as effective as the immune conjugates--while a variety 
of  inorganic  and  organic  arsenicals  (including  arsanilic  acid  and  4-arsono- 
phenyldiazotate) were essentially devoid of such effect. So, too, the proteins, 
and simple mixtures of arsanilic  acid and the proteins,  had no such effect on 
Lymphoma 6C3HED  cells in  vivo,  and this proved  true as well of various 
sulfurazoproteins  and of a number of "chemotherapeutic" agents--v/z, ameth- 
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opterin, chlorambucil, 6-mercaptopurine, azaserine,  8-azaguanine, 6-azauracil, 
thioTEPA, 5-fluorouracil, and DON, each given in maximal tolerated amounts. 
The findings will now be given in detail,  and  something will be  said further 
on of  their  implications. 
Materials and Methods 
The  methods  were  similar  to  those  previously  employed (1, 2). In brief, Lymphoma 
6C3HED cells, and those of other mouse lymphomas also, were implanted in the subcutaneous 
tissues of both groins of inbred susceptible mice, with injection of the test materials intra- 
peritoneally into arbitrarily selected groups of animals--usually  after the lymphoma cells had 
proliferated to form palpable masses (i.e., 7 days or more following implantation)--with  careful 
observation thereafter of the course of the lymphomas and the state of their animal hosts. 
For tests with Lymphoma 6C3HED cells for example, 0.5 million or more of the 6C3HED 
cells were implanted in each groin of susceptible hosts--either ZBC mice supplied by Dr. 
John Bittner or C3H/Jax mice procured from The Jackson Memorial Laboratory, Bar Harbor. 
Following such implantations, palpable lymphomas regularly appeared in the groins of un- 
treated hosts, usually after 5 to 7 days. In untreated ZBC hosts, the lymphomas enlarged 
progressively and regularly brought about death, usually within 30 days.  Some  hours or 
days following  the implantations (usually after 7 days or more, when subcutaneous lym- 
phomas approximately 1.0 cm. or more across  had become palpable in both groins), the 
materials to be tested were injected intraperitoneally  into groups of 4 or more mice. The test 
animals, together with untreated controls, were  then carefully followed,  often with daily 
weighings and observations to learn whether the injected materials were toxic,  and with fre- 
quent chartings of the palpated tumor masses, and gross and microscopic postmortem studies 
when indicated to determine the effects of the injected materials on the lymphoma cells in viro. 
Similar tests were made with Lymphoma E9514 cells in C3H/Jax  mice, with Lymphoma 
AKRL1 and L4946 cells in AKR/Jax mice, and with L1210 cells in D2BC mice. 
Preparation of Arscn@-Azoprotcins.1---4-arsonophenyldiazotate was made by a  modifica- 
tion of the procedure of Eagle and Vickers  (3),  as follows:  5 gin. arsanillc acid (Eastman) 
was dissolved in 50 mi. normal HC1, and to the solution 75 ml. water was added. The solu- 
tion was then cooled  to 0°C. in an ice bath, and 23 mi. molar NaNO~  (0*C.) was  rapidly 
added, the solution becoming pale yellow. Sufficient 2 ~ NaOH was next added to bring the 
pH, as determined with the glass electrode,  to the desired value, usually between 7.4 and 9.5, 
the color of the solution darkening as result. 8 ml. of 0.5 molar phosphate buffer (at the de- 
sired pH) was next added, and the volume adjusted to 200 ml. with HsO. 
Conjugation with one or another of the several proteins was carried out as a rule at 0*C. 
and pH 9.5 for periods of 0.5 to 8 minutes; occasionally at 22°C., with pH between 7.4 and 
8.5 for periods of 5 to 45 minutes. In the routine preparation of 4-arsonophenylazo--horse 
globulins, for example, the diazotate was mixed in equal parts with normal horse serum (gen- 
erously supplied by the Bureau of Laboratories, New York City Department of Health), with 
pH adjusted as required. After conjugation had proceeded  during the selected  interval, an 
equal volume of saturated ammonium sulfate was added to the mixture, with result in im- 
mediate precipitation of the dyed protein. The pH of the mixture was adjusted to 5.4 with 
normal HC1, and the mixture was kept 15 to 30 minutes at 37°C. The yellowish precipitate, 
recovered  by means of centrifugation, was suspended in water, and formed a reddish brown 
solution when the pH was brought to 7.4 or above; samples of this solution became yellowish 
and somewhat opalescent upon reacidification.  The reddish brown solution (pH  7.4),  was 
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dialyzed in successive changes of 0.9 per cent NaCI solution during 3 days at 40C., the di- 
alysate being then free from sulfate ions as determined with BaCL~; next it was filtered through 
a Seitz EK disc, the volume of the leddish brown filtrate being approximately equal to that 
of the serum initially employed. Samples, cultured on agar and in enriched broth, regularly 
proved sterile. 
Arsenic-azoglobulins  were also made by first precipitating the globulins from horse serum 
or rabbit serum with ammonium sulfate at half saturation, dialyzing against 0.9 per cent 
NaC1  solution, and then coupling the  sulfate-free globulins with 4-arsonophenyldiazotate, 
with  recovery  of  the  globulins  as  described  above.  4-arsonophenylazo-bovine albumin 
(Armour),  4-arsonophenylazo-bovine gamma  globulin  (Armour),  and  4-arsonophenylazo- 
casein (Nutritional Biochemicals Co.)  were  made as described above with solutions of  the 
respective proteins, usually in 4 or 8 per cent concentrations, with  acidification to pI-I ap- 
proximately 5.0 immediately after conjugation, the  uncombined diazotate being removed 
by dialysis in running tap water. Similar preparations were  made with solutions of gelatin 
(Dffco),  glladin (Mann Research Laboratories),  twice crystallized ovalbumin (Nutritional 
Biochemicals  Co.),  and  bovine glycoprotein VI  (Nutritional Biochemicals Co.).  Arsenic- 
azopeptone (Difco)  and arsenic-azohlstidine (Nutritional Biochemicals Co.)  were  also pre- 
pared  similarly  except  that  alcohol  was  used  to  precipitate  the  conjugates.  For 
control purposes, tests were made with sulfur-azoproteins prepared by conjugating the pro- 
teins with diazotized sulfanilic acid under conditions similar to those employed in the prep- 
aration of the arsenic-azoproteins. 
Assays of the Conjugates.--Us;mg an adaptation of the method of Kriectdaaus as modified 
by Low  (4),  Mr.  Walter Matnsiak, working under the supervision of Dr. C. J.  Umberger, 
Department of Forensic Medicine, Post Graduate School of Medicine, New York University, 
determined the arsenic content of a  number of the conjugatgss. Determinations of protein 
in these  specimens were made by Miss Adela Leibman, Research Associate,  Hospital for 
Special Surgery, New York, using the micro KjeldaJal procedure of/¢ieeker and Wagner (5). 
Another means of assay was more extensively employed. Observation with the naked eye 
showed that conjugates made by coupling proteins with diazotized arsanillc acid for ~  minute 
at pI-I 9.5, or for 5 minutes at pH 7.4, gave solutions with relatively faint color, while pro- 
gressively more deeply colored  solutions were obtained ff the couplings were aUowed to pro- 
ceed longer. Spectrophotometry, initially employed by Mr. Arthur Jaffe,  made plain that 
the optical densities (hereinafter OD) of solutions of arsenic-azoproteins prepared in stand- 
ardized ways were remarkably uniform. For example,  a  number of preparations made by 
mixing various lots of horse serum or rabbit serum with 4-arsonophenyldiasotate at pH 9.5 
for 30 seconds,  with recovery of the dyed azoglobulins as described  above, had optical den- 
sities of approximately 0.34 when tested in the Coleman instrument with light of 400 nap, in 
dilution 1:50, pH 7.4. Prolonging the period of coupling to one minute at pH 9.5 gave prepa- 
rations with optical densities of approximately 0.39, and coupling for 2 minutes and 8 minutes 
at pI-I 9.5 provided preparations with optical densities of 0.57 and 0.66, respectively. In gen- 
eral,  the  former preparations proved  notably effective  against established  6C3HED  cells 
growing in susceptible hosts when they were given in amounts of 0.5 to 2.0 co. per mouse 
per day on 3 to 5 successive days, as will be brought out further on, and they were devoid 
of perceptible toxic effects on the mouse hosts. 
Inhibitory Effects of Arsenic-Azoproteins on Lymphoma 6C3ttED Cells in Vivo; 
Tests wltk Other Substances 
Charts  1  and 2  show the outcome of three experiments in which tests were 
made with  arsenic-azo  conjugates prepared  respectively with  immune rabbit CH~tT 1.  Effects on Lymphoma 6C3HED ceils in v/to of arsenic-azoproteins made with (a) anti- 
lymphoma immune and (b) normal rabbit serums, respectively. 
The arsenic-azoproteins were made by mixing 50 ml. of 4-arsonophenyldiazotate with 50 ml. of 
each serum at  0°C., pH 9.5 for  1 minute, the proteins being then precipitated with ammonium 
sulfate at half-saturation, pH 5.4, suspended in 50 ml. H20 and dialyzed against 0.9 per cent NaCI 
solution. The immune globulin and normal globulin conjugates, dissolved  in 50 ml. 0.9 per cent 
NaCI  solutions, pH  7.4,  had  optical densities (hereina/ter OD)  as measured with the  Coleman 
spectrophotometer at 400 m/~, dilution 1:50, of 0.39 and 0.41, respectively. They were injected intra- 
peritoneally as indicated; so too in all subsequent experiments. 
To conserve space, oniy the tumor in the right groin of each test mouse is here charted; the op- 
posite side was comparable in every instance. So too in Chart 2 which follows. 
Experimental  Groups  and Procedures 
Four ZBC  mice  (22-28cj~)  in each group; 
all implonted with  0.5  million  6CSHEDcelIs 
in each groin 
Treatment -  2 ml., each animal,  Day 7 
1)  Untreated  controls 
2)  4 - orsonophenylozo-  immune 
robbit  globulin  (IRS 65) 
3)  4 - orsonophenylozo  -normal 
rabbit  globulin 
4)  I mgm. orsanilic acid in 
2 rnl. normal  rabbit serum 
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* N  ~  negative. All mice of groups 3 and 4 maintained their respective weights (-4-2 gin.) during the charted period; 
they remained fleshy and lively throughout an observation period of 120 days, and all proved fully susceptible  to re- 
implantation with 6C3HED cells made on the 121st day. Day 26, etc. =  died on the 26th day, etc. 
In other experiments Lymphoma  6C3HED cells implanted as above in more than 600 untreated ZBC mice have regu- 
laxly grown progressively and brought about death of the animals, with signs of generalized  lymphomatosis, usually 
within 30 days. Arsanilic acid in maximal tolerated amounts (1 to 2 reg./mouse/each  of 3 to 6 successive  days) in mixture 
with normal horse serum or globulin,  normal or immune rabbit serum or globulin,  or in 0.9 per cent NaC1 solution,  has 
proved entirely devoid of effect on 6C3HED lymphoma  cells in 190 of 194 ZBC mice. 
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CHART 2.  Effects on Lymphoma 6C3HED  cells i~z v/vo of arsenic-azoproteins made with (a)  horse 
globulin and (b) bovine albumin. 
Globulin was precipitated from 50 m]. normal horse serum with half-saturated ammonium sulfate, 
centrifuged,  suspended  in water,  and dialyzed  against 0.9 per cent NzCI solution until sulfate-free; 
then mixed in equal parts with 4-arsonophenyldiazotate pH 7.4, 0°C. 30 minutes, with recovery of the 
dyed protein as previously described. OD  (400 m~, pH  7.4,  dilution 1:50)  --  0.29.  The arsenic-azo- 
bovine albumin was prepared by mixi~lg 100m].  of 3 per cent bovine albumin (Armour-fraction V) 
with 100 ml. 4-arsonophenyldiazotate at pH 9.5 for 2 minutes; the dyed protein was then precipitated 
with ammonium sulfate (full saturation, pH 4.8)  and recovered in a  volume of 50 ml.  OD  (400 m#, 
pH 7.4, dilution 1:50)  =  0.35. 
Experimental Groups  and Procedures 
Four ZBC mice  (23- 27 gin)  in eoch gmup~ 
oil implonted  with 0.5 million 6C31-1ED  cells 
in eoch  groin 
Treatment -  2 rol., eoch onirool, Days 8,9,10 
I)  Untreated  controls 
2)  4-orsonophenylozo-horse  globulin 
3]  4-orsonophenylazo-  bovine olbumin 
4)  I mgra orsanilic ocid  in 2mL 
3%  bovine a~l)umin solution 
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*N =  negative throughout observation period (63 days). Mouse 12 died with a large subcutaneous lymphoma  in right groin and 
signs of generalized lymphomatosis  on day 50. The other animals in groups 2 and  3 were lively and  gained weight (|  to 3 gin.) 
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globulin (1), normal rabbit globulin, normal horse globulin, and bovine albumin, 
as also with arsanilic acid in simple mixture with normal rabbit serum and bo- 
vine  albumin  respectively.  It  can  be  seen  that  all  the  arsenic-azoproteins 
brought about complete and permanent regression of the 6C3HED lymphomas 
in every ZBC animal save one, while the simple mixtures of arsanilic acid and 
proteins were devoid of effect. In several similar experiments, conjugates were 
made  under  identical  conditions  with  one  or  another  of  several  batches  of 
pooled anti-6C3HED immune rabbit serum and with various batches of pooled 
normal rabbit serum. As judged by the regularity and promptness with which 
established 6C3HED  lymphomas regressed in mice given the respective con- 
jugates in various amounts, the preparations made with normal rabbit globulins 
were as potent as those made with  immune rabbit globulins---see Chart 1 for 
an example. In 41 additional experiments similar to those of Charts 1 and 2, 26 
conjugates made by mixing 4-arsonophenyldiazotate in equal parts with horse 
or rabbit serum, or with solutions of rabbit  or horse or bovine globulins,  or 
bovine albumin, regularly brought about permanent regression of established 
6C3HED  lymphomas in ZBC mice, whereas  the  lymphomas  regularly  grew 
progressively to bring about death of the hosts, usually with signs of generalized 
lymphomatosis, in more than 600 untreated  control animals. Furthermore, in 
two experiments a preparation of arsenic-azo--mouse globulin made by coupling 
mouse serum with diazotized arsanilic  acid at pH 9.5 for 2 minutes and sepa- 
rating  the  dyed  globulins  as  previously  described,  also  brought  about  the 
complete and permanent regression of established (7 day) 6C3HED lymphomas 
in  ZBC mice. 
The results of extensive tests in two experiments with  simple mixtures of 
arsanilic acid and proteins, and with various organic and inorganic arsenicals 
including  4-arsonophenyldiazotate,  are  given  in  Table  I,  together  with  the 
results  of  tests  with  nine  arsenic-azo-  and  4  sulfur-azoprotein  preparations 
made under  a  variety of conditions. 
It can be seen (Table I) that arsanilic acid, given in maximal tolerated amounts in mixture 
m~th horse globulin, bovine albumin, bovine gamma globulin, sodium easeinate, or ovalbu- 
rain, had no influence on the lymphoma ceils in dvo; the same was true of areanilic acid in 
safine solution, and  of  4-arsonophenyldiazotate, potassium  arsenite, potassium  arsenate, 
arsenic acid, carbarsone, and mapharsen, each given in maximal tolerated amounts; so too of 
the proteins given as such. The findings recorded in Table I are largely but not wholly repre- 
sentative of the outcome of numerous tests made throughout the work with arsanillc acid 
and the other arsenicals employed. For regression of established 6C3HED lymphomas was 
observed in 4 of 194 mice given repeated injections of 2.0 mi. of arsanilic acid in protein or 
NaCI solutions (0.5 or 1.0 mg..ml.), the animals in three of the exceptional instances receiv- 
ing the larger amount and showing hyperactivity and weight loss and other signs of arsenic 
toxicity during or immediately following the course of injections. The same was true of one 
of 44 mice given mapharsen, the quantity  given in this exceptional instance being almost 
lethal for the animal in question (inducing marked signs of arsenic toxicity from which, how- 
ever, the animal managed to recover) and killing the other 3 mice of its group. No instance of 
regression was observed in numerous mice given near lethal amounts of the other arsenicals JOHN o.  KInD  671 
including 4-arsonophenyldiazotate. The findings with arsanilic acid and mapharsen, although 
exceptional, make plain, however, that toxic amounts of these arsenicals can sometimes bring 
about regression of established 6C3HED lymphomas in susceptible mice. 
Five of the 9 arsenic-azoprotein preparations tested in the experiments of Table I--those 
made by conjugating 4-arsonophenyldiazotate with horse globulin, bovine albumin, bovine 
gamma globulin, sodium caseinate, and ovalbumin, respectively, were notably effective in 
overcoming established Lymphoma 6C3HED cells in susceptible mice, as the tabulated data 
show; while the four other arsenic-azoprotein preparations--those  made with bovine glyco- 
protein,  gliadin, lactalbumin,  and gelatin,  respectively--had  little or no such effect. The 
former, as can be seen from the table, besides being deeply colored (OD: 0.36 to 0.70), con- 
tained relatively large quantities of protein (21.0 to 40.2 mg./ml.)  and also relatively large 
quantities of  arsenic  (0.42 to  1.11 mg./ml.); the latter, by contrast,  although being also 
deeply colored (OD: 0.34 to 0.70) and containing large concentrations of arsenic (0.74 to 0.89 
mg./ml.),  had much lower concentrations of protein  (1.1 to 8.5 mg./ml.).  In this relation 
it should be noted that a darkly colored conjugate made with peptone and containing 2.54 
rag. arsenic/ml, was highly toxic for ZBC mice but devoid of effect on Lymphoma 6C3HED 
cells in vivo when given in maximal tolerated amounts (see footnote Table 1); also that a solu- 
tion of yellowish crystals (40 mg./ml.)  procured from a mixture of 4-arsonophenyldiazotate 
and hlstidlne, was devoid of effect on the lymphoma ceils in vivo; and that the four  sulfur- 
azoproteins, although deeply colored and containing protein in concentrations of 22.8 to 27.1 
mg./mi.,  were likewise devoid of effect on the lymphoma cells in vivo. These findings  also 
deserve consideration in relation to a larger experience with such materials. For although 
none of the numerous sulfur-azoproteins repeatedly tested throughout the work ever displayed 
any ability to overcome Lymphoma 6C3HED cells in vivo, in several additional experiments, 
colored conjugates made with bovine glycoprotein, lactalbumin, or gelatin under different 
conditions (e.g., at pH 7.4 for periods of 30 minutes or longer) acted powerfully against the 
lymphoma cells in vivo, whereas the corresponding preparations of Table I did not, as already 
stated; unfortunately these more active preparations were used up before protein and arsenic 
determinations could be made on them. 
It is noteworthy that the test mice of Table 1 tolerated much more arsenic when this was 
given as arsenic-azoprotein or carbarsone than was the case when the arsenic was admin- 
istered as potassium arsenite, potassium arsenate, arsenic acid, or mapharsen. 
The data of Table  1  suggest  that only those  conjugates containing rela- 
tively  large  quantities  of  precipitable  protein  as  well  as  relatively  large 
quantities of bound arsenic were notably active against Lymphoma 6C3HED 
cells in vivo. More will be said about this in the discussion. Meanwhile several 
observations will be cited which indicate that the proteins here employed were 
altered upon conjugation with 4-arsonophenyldiazotate. 
In this latter relation, it may be recalled that Landsteiner (6) has shown that the antigenic 
specificity of proteins is regularly altered when these are  coupled with  certain  diazotates, 
while from the work of Eagle, Smith, and Vickers (7) it can be inferred that the conditions of 
conjugation and also the character of the proteins determine the degree of alteration under- 
gone by proteins  conjugated with such substances. Several observations made during the 
course of the present work suggest that the protein components of the arsenic-azoproteins had 
been notably altered. For example, some of the arseulc-azogelatin preparations  "jelled" when 
they were chilled, while others, made under different conditions, failed to do so, this being 
the case with the gelatin conjugate of Table I. In other experiments, conjugates made with 
normal guinea pig serum and 4-arsonophenyldiazotate in proportions of 2:1 or 3:1, at pH g 
0 
.'~  -kq-  +  -k  +  -k  4" 
q-q-  ÷  ÷  ÷  -k  ÷ 
~  --kq-  --k  --k  +  --k  -k 
o  -t-q-  q-  -k  ÷  -4-  ÷ 
-~-÷  ÷  ~-  ÷  --k  --I- 
.~  ~  q-q-  --k  -k  -t-  --k  q- 
-+--k  -k  ÷  -k  ÷  -I- 
-6+  -~-  ÷  ÷  q-  d- 
r 
Jr  +  +  +  +  t~  ++  ~,  ÷q-  -6  -b  q-  -4-  ÷ 
+÷  -F  4"  q-  --k  -F 
+-I--  --I-  -k  -k  ÷  "4- 
+--k  ÷  .-b  q-  -k  -4- 
,~  -F-k  q-  -b  ÷  "4"  -k 
"  -k-q-  q-  -~  --k  +  ÷ 
q--I-  -k  -k  ÷  -Jr-  q- 
~0o  q--F  ÷  -6  -F  -4-  q~ 
-k-I-  --k"  +  -k  --k  -b 
÷--k  ÷  -6  +  -k  ÷ 
-k-I-  ÷  -b  q-  4-  -4- 
+-6  "4-  -6  ÷  -6 
-k-k  -k  -6  q-  --F  4- 
-k-k  --k  -b  ~-  -I-- 
+-4-  -~-  4"  ÷  -b 
-F-I-  -6  -b  q-  --k- 
-k-k  -k  --b  -6  -6-  4- 
-k-k  -k  -6  ÷  -41 
--k+  -k  -6  q-  4-  -b 
+-k  ÷  -b  ~  ÷ 
-~--k  q-  q-  ÷  -k  -b 
-k÷  -k  -F  +  -~-  -b 
-k-I-  +  -~  -6  ÷  -b 
-t--I-  -6  -F  q-  -q-  4- 
--k÷  -6  -F  +  -6  --b 
-k-t-  --k  ÷  q-  ÷  ÷ 
--F-F  4-  4-  4-  -6  4- 
-'r-q-  -~-  -k  -f-  -k  --b 
-k-k  -+-  -~-  -6  4-  -~ 
-6-F  q-  -~-  -f-  ÷  ÷ 
H.i 
"l~c/ 
e~  *J  e~ 
~e4  e~ 
672 ~  e,l  e,i 
ooooo  ~_  +++  ++-I-+ 
-~  ooc,  o,::,  +++  +++.~..  T 
+  ,:,oooo  -k  +++  q--l-++ 
+  o,::,,::,oo  +  +++  ++++ 
+  oooo,::,  o  +++  ++++ 
-t-  ooooo  o  ++4-  ++++ 
+  ooc,  oo  o  ++4-  ++++ 
+  ooooo  +  +++  ++++ 
+  ooooo  o  +++  ++++ 
4-  ,::,o,::,oo  ~  +++  ++++ 
+  ooooo  ~  +q-+  ++++ 
+  ooooo  o  +++  ++++ 
+  ~,oooo  o  ++,,.  ++++ 
+  ooooo  o  ++,-.  ++++ 
+  ooooo  ,:,  +++  ++++ 
+  ~,,::,,:,o~  ,::,  +++  ++++ 
+  +++++  +  +++  ++++ 
+  q-q-+++  +  ++q--  ++++ 
+  +++4-+  +  +++  ++++ 
+  +++++  +  +++  ++++ 
~'~ 
m 
.~'  o 
h~u~  ~.~  ~ 
tn 
"~  "  "  "  ~  .~ 
'q.  'q.  'q.  ~  s 
..~  ..: 
~"  ~  -~-~  ~ 
oo  o~  ~  ~_~  ~, 
673 
~I~  o  ~ 
o 674  ARSE17IC-AZOPROTEINS AND  LYM'PHOMA  CELLS 
6.4 or 7.4, 0°C., for 2 minutes--that is to say, under conditions in which somewhat less arsenic 
should  theoretically have been attached  to the proteins than was so when conjugation was 
carried  out  for  comparable  periods  at  pH  9.5,  0°C.,--were  largely  devoid  of  effect 
upon Lymphoma 6C3HED cells in vivo, whereas the untreated serum acted powerfully upon 
the cells, as in previous studies (2), the findings suggesting that the active protein constituent 
of the serum had been altered. So, too, an arsenic-azo-immune globulin which had been con- 
jugated with 4-arsonophenyldiazotate,  had much less capacity to kill Lymphoma 6C3HED 
cells in vitro in the presence of complement than had globulin separated from the untreated 
serum. 
Since  arsenic-azoproteins  with  powerful  activity  against  Lymphoma 
6C3HED ceils in vivo were regularly procured when any one of the albumins or 
globulins  employed was conjugated in equal parts  with  the  4-arsonophenyl- 
diazotatc  either at pH 9.5, 0°C., for periods of ~  to 2 minutes or at pH 7.4, 
22°C.,  for periods  of 5  to  15  minutes  or  longer--such  materials  were used 
empirically throughout the work, and systematic attempts were not made to 
define precisely the conditions of conjugation that would yield arsenic-azopro- 
reins with maximal activity and minimal toxicity. The materials varied some- 
what in optical density,  and  in  content of arsenic and protein,  as has  been 
shown.  Comparative tests disclosed  that  they varied also in capacity to act 
upon Lymphoma 6C3HED ceils in vivo, and in toxicity for the animal hosts. 
For example, a number of arsenic-azoglobulins, separated from mixtures of equal parts of 
the  4-arsonophenyldiazotate  with  normal  horse  serum  or normal  rabbit serum  which  had 
been held at 0°C., pH 9.5,  for ~  minute, had optical densities of approximately 0.34 when 
measured spectrophotometrically at pH 7.4, dilution 1: 50, nag 400. Such preparations regularly 
induced  regression of established  6C3HED  lymphomas when given to adult  ZBC mice in 
amounts of 1.0 or 2.0 ml. on 3 to 6 successive days beginning on the 8th or 10th day following 
the implantation of 0.5 million cells in each groin of the test animals. Under such circumstances 
the mice usually maintained their respective weights -4- 1 or 2 gin., and remained lively and 
devoid of signs of arsenic toxicity or other illness throughout the course of the injections and 
thereafter  (see Charts  1 and 2 for examples). Preparations made by coupling the diazotate 
and serum proteins (or with albumins or globulins separated from them) at 0°C. pH 9.3, for 
periods of 1 to 2 minutes, or at 22°C., pH 7.4, for periods of 5 to 15 minutes, usually had optical 
densities ranging from 0.42 to 0.52.  Such materials almost always induced complete regression 
of established 6C3HED lymplmmas in ZBC mice when given in amounts of 0.5 to 2.0 ml. on 
3 to 5 successive days, usually without inducing loss of weight or other signs of toxicity in the 
animal hosts. Those conjugated for longer periods--e.g., at 0°C., pH 9.3, for 8 minutes, or at 
22°C., pH 7.4, for 30 minutes or longer--in addition to being more deeply colored (OD, 0.66 
or  greater),  often  induced  regression  of  established  6C3HED lymphomaswhen given in 
amounts of 0.5 ml. on successive days. But such materials proved toxic as a  rule  (inducing 
marked tremors of the head and extremities, sometimes with eachexia and death) when given 
in amounts of 1 or 2 ml. on 3 or more successive days to ZBC mice weighing 20 to 24 gm. 
Considered  together,  the  findings  given  thus  far make plain  that  certain 
arsenic-azoproteins,  when suitably prepared and administered, regularly induce 
regression  of  established  6C3HED  lymphomas  in  susceptible mice  without 
harming the latter perceptibly, and that no such effect is brought about by the JOHN  G.  KIDD  675 
proteins employed, by simple mixtures of arsanilic  acid and the proteins,  by 
sulfur-azoproteins, or by any of a variety of inorganic and organic arsenicals 
when these are given in maximal tolerated amounts. 
Necrosis  of Lymphoma 6C3HED Cells in ZBC Mice  Treated with 
A r  senic-A zo  pr  oteins 
Lymphoma  6C3HED  cells  implanted  in  the  subcutaneous  tissues of un- 
treated ZBC mice usually begin to proliferate within 24 to 36 hours, as numerous 
studies  have  shown--the  proliferating  cells  forming  palpable  tumor  masses 
within  5  to  7 days which  enlarge  progressively until  death  of the animals, 
usually with such signs of generalized  lymphomatosis as  labored respiration, 
subcutaneous  edema,  and  palpably  enlarged  liver  and  spleen.  Postmortem 
examinations with histological  studies have shown that the proliferating lym- 
phoma cells find their way promptly to the lymph nodes of groins and  axillae, 
and  that  they can  often be found in massive numbers  in  the liver,  spleen, 
kidneys, and other viscera of the hosts in the later stages of the process. When 
the  subcutaneous lymphomas have become 2.5  to 3.5  can. across and  quite 
turgid--that is to say, during the period 16 to 26 days following implantation 
of the cells--they often press upon the overlying skin to the extent that the cells 
comprising  this become necrotic; within such growths, as also just under the 
tautly stretched skin, sheets and masses of necrotic lymphoma cells can often be 
found. One may suppose that the lymphoma cells die in such circumstances in 
consequence of turgidity or anoxia, for numerous histologic studies have  shown 
that necrotic cells are rarely to be found in the rapidly enlarging growths--meas- 
uring 1.0 to 2.0 cm. across---during  the period 7 to 14 days following implanta- 
tion (Fig. 1). By contrast, numerous observations have shown that proliferating 
Lymphoma 6C3HED cells in the groins  of ZBC mice that had been treated 
daily with suitable arsenic-azoproteins  beginning  8 to  11  days following  im- 
plantation, promply begin to die as individuals throughout the tumor masses, 
and often in proximity to dilated blood vessels, the process of necrosis continu- 
ing rapidly until no viable lymphoma cell is left. The non-neoplastic cells of the 
host animals,  by contrast, and notably those of lymph nodes, thymus, and bone 
marrow,  remained morphologically unchanged. Figs. 2, 3, and 4 illustrate  the 
findings. 
Susceptibility  of Lymphoma 6C3HED Cells to Effects  of Various 
"Anti-Lymphoma" Agents  in  Vivo:  Tests for Egects  of 
A rsenic-A zoproteins on Lymphoma Cells of Other Types 
In several tests, about which more will be said further on, arsenic-azoproteins 
that proved lethal for Lymphoma 6C3HED cells in vivo had little or no ability 
to stay the growth of Lymphoma AKRL1 or Lymphoma IA946 cells in AKR/ 
Jax mice, or that of L1210 cells in D2BC mice, even when the conjugates were 676  ARSENIC-AZOPROTEINS AND  LYMPHOMA CELLS 
given on the day of implantation and on 4 successive days thereafter in maxi- 
mal tolerated amounts.  Since normal guinea pig serum, when suitably admin- 
istered,  regularly brings  about  the  regression of  Lymphoma  6C3HED  cells 
in ~ivo (2)  but is devoid of effect on the cells of numerous other  mouse lym- 
phomas including those of  AKRL1, IA946,  and L1210,  it seemed reasonable 
to  suppose  that  the  effects  of  the  arsenic-azoproteins  and  those  of  normal 
guinea pig serum might be related, both  being dependent perhaps upon some 
special  liability  of  Lymphoma  6C3HED  cells;  and  also  that  Lymphoma 
6C3HED  cells  might be specially vulnerable to the effects of such agents as 
are capable of acting against lymphocytic cells in vivo.  Experimentation  how- 
ever, has proved the suppositions fallacious. 
Any attempt to answer satisfactorily the question whether Lymphoma 5C3HED cells are 
specially vulnerable to such agents as might act in ~ivo upon neoplastic lymphoma cells, or on 
non-neoplastic  lymphocytic cells generally, is handicapped initially by the fact, now widely 
recognized, that the "chemotherapeutic" agents thus far described in the scientific literature 
have at best only feeble and uncertain effects against the cells of mouse lymphomas in ~ivo 
(1, 8-14). Even so it seemed essential to find out whether Lymphoma 6C3HED cells are specially 
susceptible to the effects of such agents as are now available. Hence a number of tests were 
made for effects on these cells in ~/vo of the following materials, each given on 6 successive 
days in maximal tolerated amounts: amethopterin, chlorambucil,  6-mercaptopurine,  8-aza- 
guanine,  ThioTEPA,  asaserine,  6-azanracil,  DON,  and  5-fluorouracil.  2 In extensive trials, 
none of these chemical compounds had any such effect, though when given in toxic but sub- 
lethal amounts, both DON and 5-fluorouracil brought about a transitory softening  of sub- 
cutaneous lymphomas in the test mice and some slight prolongation of host survival time. 
The findings recorded  in Table II are representative of a considerably larger experience in 
attempts to influence established 6C3HED lymphomas in ZBC mice with these compounds. 
It can be added that in several other experiments none of these materials prevented the de- 
velopment  of palpable 6C3FIED  lymphomas and generalized  lymphomatosis in ZBC mice 
when each was given in maximal tolerated amounts to a group of 4 implanted mice on the day 
of implantation and on each of the succeeding 4 days--under conditions, that is to say, which 
were propitious for the action of the chemical compound and unfavorable for the survival of 
the lymphoma cells; this has also proved true of cortisone. 
By contrast, adequate experimental materials were  at hand for resolving  the question 
whether arsenic-azoproteins  and normal guinea pig serum exert their effects on Lymphoma 
6C3HED  cells in vivo through some related means.  For by undertreating C3H/Jax  mice 
carrying established 6C3HED lymphomas,  Dr. Nelson Holmqnist and I  have recently pro- 
duced two sublines of Lymphoma 6C3HED  cells which, although identical with the original 
line of 6C3HED cells  in morphology and in growth characteristics upon transplantation in 
susceptible  mice, have proved totally refractory to the effects of guinea pig serum  during 
more than 20 serial transplantations. Both of the serum-resistant sublines are susceptible to 
the effects of arsenlc-azoproteins,  as several experiments  have shown.  Table III gives the 
findings of a representative experiment. 
Acting for the  original sources,  Dr.  Chester  Stock of The  Sloan-Kettering Institute 
generously  supplied the chemical compounds.  Throughout the paper, the terms DON and 
thioTEPA have been used  to designate 6-diazo-5-oxo-norleucine and N, N', N ~, triethyl- 
enelmino thiophosphoramide,  respectively. JOHN  G.  KIDD  677 
Mention  has already  been  made  of the  fact,  dearly  shown in  several  experiments and 
documented in Table IV, q.v.,  that arsenic-azoprotein preparations--each capable of acting 
powerfully upon Lymphoma 6C3HED cells,  as was shown in subsidiary tests--had relatively 
little or no effect on the cells of Lymphomas AKRL1 and IA946 in AKR mice, or upon those 
TABLE  II 
Tests for  Effects  of  Various  "Chemotherapeutic"  Agents  on  Lymphoma  6  C3HED  Cells  in  Vivo 
Experimental groups 
4 ZBC mice (22-28 gm.) in each 
group--all implanted with 0.5 million 
6C3HED cells in each groin, day 1 
Intraperitoneal  injections:  2.0  ml. 
each animal, days 8 to 13 
1. Nil--untreated  controls 
2. 4-arsonophenylazo--bovine  al- 
burain, OD--0.53 
3. Amethopterln, 0.08 mg./ml. 
4.  "  0.04  "  " 
5.  "  0.02  "  " 
6.  "  0.01  "  " 
Outcome 
Growths in 4 test mice 
Days following  implantation: 
8  12  15  18  22  Subsequent  course 
++++  ++++  ++++  ++++  ++++  GL-died--days23, 23, 26, 27 
++++  0000  0000  0000  0000  Allsurvived--60days 
++++  ++++  ++++  ++++  ++++  GL-died--days23, 27, 27,31 
++++  ++++  ++++  ++++  ++++  GL-"  "  25, 29, 29, 29 
++++  ++++  ++++  ++++  ++++  GL-"  "  23, 23, 28, 28 
++++  ++++  ++++  ++++  ++++  GL-"  "  21, 25, 28, 28 
7. Chlorambucil, 0.16 mg./ml. 
8. 6-Mercaptopurine, 0.03  mg./ml. 
9. 8-Azaguanine 0.75  mg./ml. 
10. ThioTEPA,  0.04  mg./ml. 
11. Azaserine 0.20 mg./ml. 
t2.  "  0.10  "  " 
13.  6-Azanracil, 5.0 mg./ml. 
14. DON 0.004 mg./mL 
15.  "  0.002  "  " 
16.  "  0.001  "  " 
17. 5-Finorouracil, 0.5 mg./ml. 
18.  "  0.25  "  " 
"}-++-~  -{-+-[-+  ++++  -{-+++  ++-4-+  GL-died--days25.  25, 27, 27 
++++  ++++  ++  ++  ++  GL-died--days 12, 14, 30, 31 
++++  ++++  ++++  +++  +++  GL-died--days 15, 25, 27, 29 
++++  ++++  ++++  ++++  ++++  GL-died--days 23, 23, 23, 23 
++++  ++++  ++++  +++  +++  GL-died--days 14, 28, 29, 30 
++++  ++++  ++++  ++++  ++++  GL-"  "  25, 26, 30, 31 
++++  ++++  ++++  +++  +++  GL-died--days 15, 23, 26, 27 
++++  ? ? ? ?  ? ? ? ?  +++  +++  GL-died--days 17, 27, 31, 35 
++++  ++++  ? ?++  ++++  ++++  GL-  "  "  26, 31, 31, 32 
++++  ++++  ++++  ++++  ++++  GL-  ....  27, 29, 29,30 
++++  ++++  ? ? ? ?  ++++  ++++  GL-died--days30. 31, 33, 35 
++++  ++++  ++++  ++++  ++++  GL-  ....  27, 27, 29, 29 
Each material was given in maximal tolerated amounts as determined beforehand on 22 to 28 gin. ZBC mice. 
+-[-+-t-,  growths in both groins of each test mouse, approximately 1.0 cm. across on day 8, enlarging progressively 
thereafter as in the untreated control animals. 
GL, signs of generalized lymphomatosis. 
?, palpable mass, softer and usually smaller than those in groins of control animals. 
0, no palpable tumors, mouse sleek and lively. 
of Lymphoma L1210 in D2BC or DBA mice. The effects of arsenic-a2oproteins on the cells of 
Lymphoma E9514--a transplanted growth that originated in a  C3H/Jax mouse in the labora- 
tory of Dr.  George Snell of The Jackson Memorial Laboratories, Bar Harbor, and the only 
other lymphoma against which the arsenic-aea)proteins have been employed thus far--have 
interest in this and other relations. For although guinea pig serum has no effect on the cells 
of Lymphoma E9514 in ~vo, as many tests have shown (1), the arsenlc-azoproteins act power- 678  ARSENIC-AZOPROTEINS AND  LYMPHOMA  CELLS 
TABLE  III 
Effects  of Arsenic-Azoproteins  on Sublines of 6C3HED  Cells  that are Resislanl to 
the  Effects  of Guinea Pig  Serum  in  Vivo 
Experimental groups  Growths in four test mice of each group 
I. 4 ZBC mice in each group--all im- 
planted in each groin with 0.2 mil- 
lion 6C3HED  cells of original line; 
~iven intraperitoneal injections  as 
indicated 
1.  Untreated controls 
2. Given normal guinea pig serum, 2 
ml. each animal, days 8 to 10 
3.  Given 1.0 n~.  arsanilie acid in  2 
mL normal horse globulin,  each 
animal, days 8 to 10 
4.  Given  4-arsenophenylazo-horse 
globulin (OD -  0.34) 2 ml., each 
animal, days 8 to 10 
5.  Given  4-arsenophenylazo-horse 
globulin (OD =  0.46), 1 ml., each 
animal, days 8 to 10. 
II. 4 ZBC mice in each group--all im- 
planted in each groin with 0.2 mil- 
lion 6C3HED  cells of resistant 
subline  IRG; given intraperitoneal 
injections  as indicated 
1. Untreated controls 
2.  Given normal guinea pig serum, 2 
ml., each animal, days 8 to 10. 
3.  Given 1.0 mgm. arsanilic acid in 2 
ml. horse globulin,  each animal, 
days 8 to 10 
4.  Given  4-arsonophenylazo-horse 
globulin (0]3 =  0.34) 2 mL, each 
animal, days 8 to 10 
3.  Given  4-arsonophenylazo-horse 
globulin (OD  ~  0.46) 1 mL, each 
animal, days 8 to 10 
IIL 4ZBC mice in  each  group---all im- 
planted in each groin with 0.2 mil- 
llon 6C3HED cells of resistant 
subline 2 RG; given intruperitoneal 
injections  as indicated 
1. Untreated controls 
2.  Given normal guinea pig serum--2 
ml., each animal, days 8 to 10 
3.  Given 1.0 ms. arsanilic acid in  2 
nd.  horse globulin,  each animal, 
days 8 to 10 
4.  Given  4-arsonophenylazo-horse 
globulin (OD =  0.34) 2 ml. each 
animal, days 8 to 10 
5.  Given  4-arsonophenylazo-horse 
globulin (OD  =  0.46) 2 ml., each 
animal, days 8 to 10 
Days:  Subsequent  course  8  It  23  21 
q-q-q-q-  q-q-q-q-  +q-q-q-  +q-q-q-  GL-died--days  23, 24, 26, 28 
q-q-q-+  0  0 0 0  0 0 0  0  0  0 0 0  Allsurvived--60dsys 
q-q-q-q-  +q-q-q-  ++q-q-  q-q-+q-  GL-dled---days24, 24, 26, 28 
q-q-q-q-  0 0  0 0  0 0 0 0  0  0 0 0  Allsurvived--60days 
q-q-q-q-  0 0 q-q-  0 0 0  0  0 0 0 q-  Threemicesurvived60days; 
one, GL-died---day  32 
Days:  Subsequent  course  8  11  15  21 
+q-q-q-  q-q-q-q-  q-q--b+  q-q-q-q-  GL-died-days 23, 28, 29, 32 
q-q-q-q-  -t-q-q-q-  q-q-q-q-  q-q-q-q-  GL-died-days 24, 26, 28, 32 
0q-q-q-  0 q-+q-  0 -I-q-q-  0 q-q-q-  One  mouse  survived  60 
q-q-q-q-  0000  0000  0000 
q-q-+q-  oooo 
days,  Other  three:  GL- 
died--days 26, 28, 32 
All survived---60 days 
0 0 0 0  0 0  0 0  Allsurvived--60days 
21  Subsequent course 
q-q-q-q-  GL-died-days 26, 28, 28, 29 
q-q-q-q-  GL-died-days 24, 25, 26, 28 
q--H-q-  GL-died-days 24, 25, 25, 28 
0  0 0  0  All survived--60 days 
0 0  0 0  All survived--60 days 
D~s: 
8  II  15 
++++  ++++  ++++ 
++++  ++++  ++++ 
++++  ++++  ++++ 
++++  oooo  oooo 
++++  0000  0000 
+q-+q-, growths in both groins of each test mouse, approximately 1.0 cm. across on day 8, enlarging pro- 
gre~sively  thereafter as in the uutreated control animals. 
GL,  signs  of  generalized lymphomstosis. 
0,  no palpable tumors, mouse sleek  and lively. IOHI',I o.  X~D  679 
fully upon them, as is shown in one of the experiments summarized in Table IV. In this test, 
it can be seen that C3H/Jax mice, implanted with E9514 cells and treated with one or the 
other of two arsenic-azoprotein preparations on the day of implantation and on each of the 
succeeding 2  days, all failed  to  develop palpable  lymphomas and remained lively,  without 
signs of lymphomatosis, throughout an observation period of 42 days, while untreated control 
animals without exception developed palpable subcutaneous lymphomas and died with signs 
of generalized lymphomatosis during the period 15 to 20 days. This result was substantiated 
in  a  subsequent experiment.  Furthermore  in four  additional  experiments fully established 
TABLE  IV 
Tests for Effect, of Arsmic-azoproteins  on  Calls of Lymphoraa~ EgM4, L1210, and L4946  in  Vivo 
Experiments  and  experimental  Growths in  four  test mice of each group 
groups 
I. 4 C3H/Jax mice in each group--all implanted  Days following implantation:  with 0.5 million E9$14 cells in each groin. 
Each animal given 2 rot. on days 1, 2, 3:  8  11  14  18  Subsequent course 
1. Nil--untreated controls 
2. 4-arsonophenylazo-horse globulin, OD--0.38 
3. 4-arsonophenyl-bovine  albumin, OD--0.26 
II. 4 AKR/Jax mice  in each group--all implan- 
ted  with 0.06 million IA946 cells in each 
++-}-+  +--]-+-.}- ++++  +--}-++  OL-died---days 15, 20 
0 00 0  00 00  00 0 0  00 00  All survived (42 days) 
0000  0000  0000  0000  "  "  " 
Days following implantation:  Subsequent course 
9  11  14  groin.  Each animal given 2 mL, days 1, 2, 
3, 4, 5: 
1. Nil--untreated controls 
2. 4-arsonophenylazo-horse globulin OD--0.38 
3. 4-arsonophenylazo-horse globulin OD---0.46 
4. 4-arsonophenylazo-boviue albumin 0D--0.26 
5. 4-arsonophenylazo-bovine albumin OD---0.42 
III. 4D2BC mice  in each  group:all implanted 
with  0.02 million  LI210 cells in eachgroin. 
Each animal given 2 mL, days 1, 2, 3, 4, 5: 
1. Nil--untreated controls 
2. 4-arsonophenylazo-horse  globulin OD--0.38 
3. 4-arsonophenylazo-horse  globulin OD--0.46 
4. 4-arsonopheuylazo--bovine albumin OD--0.26 
5. 4-arsunophenylazo-bovine  albumin OD--0.42 
++++  ++++  ++++  GL-<lied--,days  16, 16, 1617 
++++  +++÷  ÷+++  ......  16, 16, t6, 17 
++++  -I-+++  ++++  "  "  "  16, 16, 16, 17 
-{-+++  ++++  ÷+++  .....  '  16, ~6, 16, 17 
++÷+  ++++  +-I-÷+  ......  16, 16, 16. 16 
Days following implantation: 
11  14  16  Subsequent course 
0 0++  +++--}-  --~-[--.[---~- GL-died----days  16, 17, 17, 21 
0  0++  ?  P -.J-+  -}---[-++  ......  18, 19, 21, 21 
00+÷  ??÷+  ÷÷++  ......  t9,19,  tg, 21 
0  0+-{-  ?  ? +÷  ++++  "  ....  IS, tg, 2L 21 
0  0-{-+  ?  ?÷+  ÷+++  ......  19, 20, 21, 21 
++++,  growths in both groins of each test mouse, approximately  1.0 cm. across on day 8 enlarging progressively 
thereafter as in the untreated control animals. 
GL, signs of generalized lymphomatosis. 
0, no palpable  tumors, mouse sleek and lively. 
subcutaneous E9S14 lymphomas (which measured 0.8 to 1.2 mm across on the 8th day follow- 
ing implantation) promptly dwindled and disappeared when one or another of several arsenic- 
azoproteins was injected intraperitoneally  on 3  to 5  successive days beginning on day 8  in 
each of 16 mice. Within a few days, however, all the treated mice manifested palpably enlarged 
livers and spleens, and they all soon sickened and died,  usually within a  day or 2  following 
death  of the  untreated  controls,  histologic studies showing that  the groins of the  treated 
animals were devoid of Lymphoma E9514 cells while their livers and spleens were massively 
invaded. 680  ARSENIC-AZOPROTEINS  AND  LYMPHOMA  CELLS 
It remains to be learned why the arsenic-azoproteins  should fail to stay the 
growth of Lymphoma E9514 cells in livers and spleens of susceptible mice while 
overcoming them in subcutaneous tissues; and also why the conjugates, while 
capable of acting powerfully upon Lymphoma 6C3HED cells in vivo, should 
prove devoid of effect upon the cells of Lymphomas AKRL1, L1210, and L4946. 
DISCUSSION 
Only  those  conjugates  containing  arsenic  in  combination  with  relatively 
large  amounts  of protein  were notably effective in  overcoming  Lymphoma 
6C3HED  cells in vivo (Table I).  Taken  together with  the other findings  of 
the work, the fact suggests that the arsenic,  when combined with protein in 
this way, acts directly and presumably to some extent selectively on the pro- 
liferating  lymphoma  cells,  though  precisely why this  should be so remains 
unknown.  For,  although  much is known about the pharmacologic and  toxic 
effects  of arsenic  upon mammalian organisms  (15),  and  much also about its 
selective effects upon spirochetes and  trypanosomes  (16),  relatively little  is 
known of its effects upon mammalian  cells as such,  though in this relation, 
Forkner some time ago employed potassium arsenite extensively in the treat- 
ment of chronic myelogenous leukemia in human beings (17, 18), while Dusfin 
has  shown that  sodium cacodylate can  arrest  division and  produce nuclear 
abnormalities in mouse sarcoma cells (19),  and Fell and Allsopp  have noted 
that lewisite is highly toxic to cultured embryonic cells (20), perhaps in part 
because of its action upon sulfhydryl enzyme systems essential for their me- 
tabolism (15). In relation to the part played by the protein component of the 
arsenic-azo  conjugates, it may be significant  that  such conjugates are anti- 
genic, as Landsteiner has shown (6); hence it may be inferred that they enter 
into close association with living cells. Furthermore, a number of other work- 
ers--notably Sabin (21), Madden and Whipple (22), Oliver (23), and Brachet 
(24)--using diverse experimental materials and methods, have provided evi- 
dence that living mammalian cells can take in and metabolize proteins, while 
Busch and  Greene  (25),  and  Kent and Gey (26)  have recorded observations 
indicating that this is true of certain tumor cells as well. Certainly the possi- 
bility exists  that in the present work the protein component might somehow 
have brought  the  conjugated arsenic  into  close  association with  lymphoma 
cells, thus giving rise to the effects here described. To learn through experiment 
whether this be so is another matter, however, as is also the question whether 
the bound arsenic induces necrosis  of Lymphoma 6C3HED cells  in vivo by 
acting upon essential  sulfhydryl enzymes. 
Whatever  the  means  may  be  whereby  arsenic-azoproteins  bring  about 
necrosis of Lymphoma 6C3HED cells in vivo, it is obvious that the conjugates 
failed under more or less comparable circumstances to act conspicuously on 
mouse lymphoma cells of several other types. For although  the arsenic-azo- 
proteins readily overcame Lymphoma E9514 cells growing in the subcutaneous JOHN  G.  KIDD  681 
tissues  of susceptible mice,  they had  little or no effect once these  cells had 
reached the livers and spleens of susceptible hosts, and they were essential]y 
devoid of effect in vivo on the cells of Lymphomas AKRL1, L4946, and L1210 
(Table  IV).  In  this  relation,  special  interest  centers  around  the  fact  that 
Lymphoma  6C3HED  cells  are  highly  susceptible  in  vivo  to  the  effects  of 
arsenic-azoproteins and to those of guinea pig serum  (1,  2).  Since the conju- 
gates  are  effective against  sublines  of Lymphoma  6C3HED  cells  that  are 
resistant  to  the effects of guinea pig serum  (Table III),  it is  clear that  the 
arsenic-azoproteins  and  guinea  pig  serum  probably  act  through  unrelated 
means. Furthermore, since Lymphoma 6C3HED cells are largely uninfluenced 
in dvo  by amethopterin, chlorambucil, 6-mercaptopurine, 8-azaguanine,  aza- 
serine, 6-azauracil, 5-fluorouracil, ThioTEPA, and DON (Table II), it seems 
plain that they are not specially liable to the effects of such "chemotherapeutic" 
compounds as have been widely presumed to act upon lymphoma cells gen- 
erally. The findings deserve consideration in relation to the results of numerous 
attempts made heretofore to overcome proliferating lymphoma cells in  sus- 
ceptible mice under controlled experimental conditions. 
Much work by others has shown that certain chemical compounds, although often 
proving toxic for the animal  hosts  in the amounts given,  have exerted effects--at 
best only feeble and uncertain--upon a  few types of lymphoma cells in rive while 
being devoid of noteworthy effect on lymphoma cells of other types, as is now widely 
recognized (1, 8-14).  So, too, immune serums, prepared in rabbits with mouse lym- 
phoma cells as antigens,  share these limitations,  though in lesser degree;  for while 
such serums have acted upon all the mouse lymphoma cells thus far exposed to their 
effects in v/~o, they have proved considerably more effective against  the cells of some 
lymphomas than against  those of others,  and none has been sufficiently powerful to 
cure susceptible  mice  with  advanced lymphomatosis  (1).  By contrast, guinea  pig 
serum,  when suitably prepared and  administered,  regularly cures  susceptible  mice 
with advanced 6C3HED lymphomatosis,  its effects in this relation being far more 
powerful than are those of any other antilymphoma agent thus far described in the 
scientific literature (1, 2, 27); yet it has proved devoid of effect upon all but two of 
the 14 types of mouse lymphoma cells tested thus far (1). 
From the foregoing, at least two inferences can be drawn: (a) that lymphoma 
cells of a single type may be highly susceptible to the effects of diverse "anti- 
lymphoma" agents (which act in different ways upon them) and at the same 
time prove refractory to the effects of other "anti-lymphoma" agents, and (b) 
that  wide differences exist between various  types  of mouse  lymphoma cells 
that  resemble  one another  quite  closely in  growth  characteristics  following 
transplantation  in  susceptible mice and  in morphologic characters as  deter- 
mined by ordinary means,  s More refined methods than those hitherto employed 
3  In this relation, Shrek, Friedman, and Leithold have recently provided evidence that 
neoplastic lymphocytes of human beings differ widely in sensitivity to the effects of x-rays 
and chemotherapeutic  agents in vitro (J. Nat. Cancer Inst.,  1958, ~t0, 1037). 682  ARSENIC-AZOPROTEINS AND  LYM'PHOMA CELLS 
will obviously be required to define precisely the means whereby anti-lymphoma 
agents exert their effects upon lymphoma cells in v/vo, and the nature of the 
intrinsic  differences  between lymphoma cells of various types. In these rela- 
tions,  it  remains  to  be  learned  whether  other  metallo-protein  compounds 
will act upon lymphoma cells in vivo and thus perhaps disclose more about their 
nature,  and  also whether a  cytotoxic chemical  can be attached to anti-lym- 
phoma immune globulins  in such a  way as to enhance their effects on lym- 
phoma cells in vivo. 
SUMMARY 
Conjugates made by coupling  diazotized arsanilic  acid with one or another 
of a  variety of proteins  regularly brought  about the complete regression  of 
established 6C3HED lymphomas in living  mice without perceptibly harming 
the latter, while untreated control animals regularly died with lymphomatosis. 
Histologic studies made plain that the lymphoma cells promptly die in  mice 
treated with the arsenic-azoproteins,  while those in untreated control animals 
continue  to proliferate.  Various  inorganic  and  organic  arsenicals  (including 
arsanilic  acid and 4-arsonophenyldiazotate) were essentially devoid of effect on 
the lymphoma cells in ~/vo, and this proved true as well of the proteins employed 
(serum  albumins  and  globulins  procured  from  several  species,  casein,  and 
ovalbumin). Mixtures of arsanilic  acid and the several proteins, various sulfur- 
azoproteins,  and  a  number  of  other  substances--dz.,  amethopterin,  chlor- 
ambucil,  6-mercaptopurine,  8-azaguanine,  azaserine,  6-azauracil,  5-fluoro- 
uracil,  thioTEPA, and DON, each given in maximal tolerated amounts--also 
failed to influence  notably the course of established 6C3HED lymphomas in 
v/vo. 
Although  readily overcoming Lymphoma E9514 cells growing  in the sub- 
cutaneous tissues of susceptible mice,  the arsenic-azoproteins  had little or no 
effect once these cells had reached the livers  and spleens  of susceptible hosts. 
Furthermore the arsenic-azoproteins  had little or no effect in dvo on the cells 
of Lymphoma AKRL1, L1210, and L4946. 
The findings were considered in relationship to the respective susceptibilities 
of several types of lymphoma cells to other anti-lymphoma agents--notably 
guinea pig serum, immune serums prepared in rabbits with mouse lymphoma 
cells as antigens,  and a  variety of chemical  compounds. Taken together,  the 
observations provide proof that lymphoma cells of various types, although re- 
sembling one another  quite closely in growth characteristics following  trans- 
plantation in susceptible hosts,  and  in morphology as disclosed  by ordinary 
microscopy,  differ  notably  in  susceptibility  to  the  effects  of  the  several 
anti-lymphoma agents. 
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EXPLANATION OF PLATES 
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The photographs were made by Mr.  Julius Mesiar and Dr. Harry Browne.  The 
sections were  stained  with  methylene  blue and  eosin. 
FIG. I. Lymphoma 6C3HED  cells proliferating in the subcutaneous areolar tissue 
of a  ZBC mouse on  the  13th  day following implantation  of 0.5  million lymphoma 
cells in each groin. Four  additional  untreated  mice implanted at the same time all 
had  progressively enlarging  lymphomas and  died  respectively on  days 24,  26,  28, 
29. Initially  X  800; enlarged  to approximately  X  1400. 
FIG.  2.  Necrotic  and  degenerating  Lymphoma 6C3HED  cells  in  the  groin  of a 
ZBC mouse that had been treated with arsenic-azo horse globulin. 0.5 million lym- 
phoma  cells  had  been  implanted  in  each  groin  on  day  l--same  cell  suspension 
as used in  the  animal  of  Fig.  l;  on  day  8,  tumors  measuring  1.2  and  1.3  cm. 
across were present  in  left  and  right  groins;  on  days  10  to  12,  2  ml.  arsenic-azo 
horse  globulin  (OD:  0.46)  were  given  intraperitoneally.  Tumors  procured  for 
histologic  study  on  day  13.  Permanent  regression  of  lymphomas  in  4  additional 
animals  given  the  same  arsenic-azoprotein  preparation  on  days  |0  to  14--2  ml., 
each mouse, each day. Initially  X  800; enlarged to approximately  X  1400. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 108  PLATE  44 
(Kidd: Arsenic-azoproteins and lymphoma cells) PLATE 45 
FIG. 3.  Necrotic lymphoma  cells in  the  groin of a  second  treated  mouse  of  the 
same  experiment.  2  ml.  arsenic-azo bovine albumin,  OD:  0.36,  given  on  days  l0 
and  l 1;  tumors procured for  histologic study on  day  12.  This  arsenic azo protein 
preparation also brought about permanent regression of 6C3HED  lymphomas in 4 
additional ZBC mice  each  given 2  ml.,  days  10  to  14.  Initiallv X  1260;  enlarged 
to approximately X  1700. 
FIG. 4.  Necrotic lymphoma cells in  the  growth  of  the  opposite groin of  treated 
mouse  of Fig.  1.  Initially X  1260; enlarged to approximately ×  1700. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  108  PLATE  45 
(Kidd: Arsenic-azoproteins and lymphoma cells) 